JeffreyMJacobsonMD
Infectious Disease • Philadelphia, PAProfessor, Drexel University School of Medicine
Are you Dr. Jacobson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3401 N Broad St
Philadelphia, PA 19140Phone+1 215-707-3807Fax+1 215-707-4414
Summary
- Dr. Jeffrey Jacobson, MD is an infectious disease specialist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, Ohio, and New York. He is affiliated with University Hospitals Cleveland Medical Center and is a Professor at Drexel University School of Medicine.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1980
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1977 - 1978
Weill Cornell MedicineClass of 1977
Certifications & Licensure
OH State Medical License 2019 - 2026
PA State Medical License 2006 - 2021
NY State Medical License 1978 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
- Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV Start of enrollment: 2001 Feb 01
- Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsA Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy.Rachel M Presti, Eunice Yeh, Brett Williams, Alan Landay, Jeffrey M Jacobson
Open Forum Infectious Diseases. 2021-12-01 - 8 citationsFour Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May ...Brett Williams, Stefan J. Green, Ronald J. Bosch, Ellen S. Chan, Jeffrey M. Jacobson
Pathogens & Immunity. 2019-09-23 - 61 citationsRifaximin Has a Marginal Impact on Microbial Translocation, T-cell Activation and Inflammation in HIV-Positive Immune Non-responders to Antiretroviral Therapy – ACTG A...Allan R. Tenorio, Ellen S. Chan, Ronald J. Bosch, Bernard J.C. Macatangay, Sarah W. Read
The Journal of Infectious Diseases. 2015-03-01
Press Mentions
- University Hospitals and CWRU Join Global Study of AstraZeneca’s COVID-19 VaccineOctober 29th, 2020
